share_log

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Alnylam Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

阿里拉姆制藥 | 10-Q：2024財年三季報
美股SEC公告 ·  2024/10/31 08:25

Moomoo AI 已提取核心訊息

Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year, primarily due to lower collaboration revenues. Net product revenues grew 34% to $420.1 million, driven by AMVUTTRA's 74% increase to $258.6 million. The company posted a net loss of $111.6 million for the quarter.Research and development expenses rose 7% to $270.9 million, reflecting increased clinical trial costs for zilebesiran and mivelsiran programs. Selling, general and administrative expenses increased 11% to $221.0 million due to higher marketing investments for TTR therapies and employee compensation.Alnylam ended Q3 with $3.1 billion in cash and investments. The company expects continued growth in R&D and SG&A expenses in 2024 as it advances its pipeline and prepares for potential launches. Management believes current cash reserves and expected revenues will fund operations for at least the next 12 months.
Alnylam Pharmaceuticals reported Q3 2024 total revenues of $500.9 million, down 33% year-over-year, primarily due to lower collaboration revenues. Net product revenues grew 34% to $420.1 million, driven by AMVUTTRA's 74% increase to $258.6 million. The company posted a net loss of $111.6 million for the quarter.Research and development expenses rose 7% to $270.9 million, reflecting increased clinical trial costs for zilebesiran and mivelsiran programs. Selling, general and administrative expenses increased 11% to $221.0 million due to higher marketing investments for TTR therapies and employee compensation.Alnylam ended Q3 with $3.1 billion in cash and investments. The company expects continued growth in R&D and SG&A expenses in 2024 as it advances its pipeline and prepares for potential launches. Management believes current cash reserves and expected revenues will fund operations for at least the next 12 months.
阿里拉姆制藥報告了2024年第三季度的總收入爲50090萬美元，同比下降33%，主要是由於合作收入減少。淨產品收入增長34%，達到了42010萬美元，這得益於AMVUTTRA的收入增長74%，達到25860萬美元。該公司本季度的淨虧損爲11160萬美元。研發費用增加7%，達到27090萬美元，反映了zilebesiran和mivelsiran項目的臨牀試驗成本增加。銷售、一般和行政費用增加11%，達到22100萬美元，原因是TTR療法的市場投資和員工薪酬增加。阿里拉姆在第三季度結束時擁有31億現金和投資。公司預計在2024年，隨着其管線的發展和潛在上市的準備，研發和銷售、一般和行政費用將持續增長。管理層相信，當前的現金儲備和預期收入將會支持至少未來12個月的運營。
阿里拉姆制藥報告了2024年第三季度的總收入爲50090萬美元，同比下降33%，主要是由於合作收入減少。淨產品收入增長34%，達到了42010萬美元，這得益於AMVUTTRA的收入增長74%，達到25860萬美元。該公司本季度的淨虧損爲11160萬美元。研發費用增加7%，達到27090萬美元，反映了zilebesiran和mivelsiran項目的臨牀試驗成本增加。銷售、一般和行政費用增加11%，達到22100萬美元，原因是TTR療法的市場投資和員工薪酬增加。阿里拉姆在第三季度結束時擁有31億現金和投資。公司預計在2024年，隨着其管線的發展和潛在上市的準備，研發和銷售、一般和行政費用將持續增長。管理層相信，當前的現金儲備和預期收入將會支持至少未來12個月的運營。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間